CALCULATE YOUR SIP RETURNS

Supriya Lifescience Shares Dropped Over 2% Despite Starting New API Production Block

Updated on: Dec 30, 2024, 5:57 PM IST
The new facility was developed with an investment of ~₹125 crore and is likely to increase the capacity by 335 kiloliters.
Supriya Lifescience Shares Dropped Over 2% Despite Starting New API Production Block
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

On December 17, 2024, Supriya Lifescience Ltd. (SLL), a leader in the pharmaceutical industry, announced that it has commenced a new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site.

The company in the exchange filing stated that this facility, developed with an investment of approximately ₹125 crore, adds a substantial 335 kiloliters to the company’s production capacity, increasing its Lote Parshuram capacity by over 55%, from 597 KLPD to 932 KLPD. This expansion is a key step in the company’s ambitious growth strategy.

Focus on R&D and Product Innovation

The new production block is strategically designed to enhance SLL’s R&D capabilities and support the scaling up of its product pipeline. Several innovative products in niche therapeutic areas are nearing commercialization, underscoring the company’s commitment to securing a leadership position in these markets through efficient processes and backward integration.

Key Features of the New Facility

  • Backward Integration Model: The facility is designed to support SLL’s backward integration model, providing economies of scale and a competitive advantage.
  • Facility Layout: Spanning 5,000 square meters and structured across four levels, the facility is optimized for efficient operations and safe workflows.
  • Reactor Capacity: The facility is equipped with 33 reactors, including both stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL.
  • Process Efficiency: The design utilizes gravity-based process flows to enhance safety, maintain product integrity, and optimize operational efficiency.
  • Safety and Automation: Closed-system handling is incorporated at critical stages, with advanced process control automation and material handling systems ensuring compliance with the highest quality standards.
  • Adaptability: The facility is designed to accommodate a variety of unit processes and operations, making it adaptable to future needs and technological advancements.

Dr Satish Wagh, Executive Chairman & WTD, Supriya Lifescience Ltd, commenting on the occasion, said, – “We are excited to inaugurate our new manufacturing Module E block today. With the latest technologies and our team’s dedication, we are poised to elevate product quality, ensure efficiency through backward integration, and meet growing global demand. Module E is a testament to our strategic focus on innovation and sustainability, serving as a key driver of growth while reducing dependence on imports. As SLL continues to strengthen its infrastructure and expand its product porƞolio, the company remains dedicated to setting new benchmarks in the pharmaceutical industry and delivering value to its stakeholders”

On December 18, 2024, Supriya Lifescience shares opened at ₹734.50 and touched the day low of ₹715.00 at 09:30 AM.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

Published on: Dec 18, 2024, 9:35 AM IST

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 2.5 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 2.5 Cr+ happy customers